Rituximab for the first-line treatment of chronic lymphocytic leukaemia
National Institute for Health and Clinical Excellence
Record ID 32011000092
English
Authors' recommendations:
Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide is considered appropriate.Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia.
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/nicemedia/live/11907/44906/44906.pdf
Year Published:
2009
URL for published report:
http://www.nice.org.uk/TA174
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Antibodies, Monoclonal
- Leukemia, Lymphocytic, Chronic, B-Cell
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.